Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Green Valley Given US Go-Ahead for Phase III Alzheimer's Trial

publication date: Apr 27, 2020

Shanghai Green Valley Pharma has been given permission to start a US arm of its global Phase III trial of its novel treatment for Alzheimer's, which is derived from marine brown algae. The product was approved and launched last year in China following clinical trials. Oligomannate (GV-971) is a mixture of acidic linear oligosaccharides, delivered orally. In the China Phase III trial, patients who received oligomannate showed a mean gain of 2.54 in their ADAS-Cog12 Scores. The treatment is thought to work by reshaping the balance of gastrointestinal microbiota. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital